北京时间：8月28日 19:45-21:00

2026 ESC Guidelines for the Management of Heart Failure

2026 ESC心力衰竭管理指南

北京时间：8月29日 19:45-21:00

2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease

2026 ESC心血管疾病与慢性肾脏病管理指南

北京时间：8月30日 19:45-21:00

5th Universal Definition of Myocardial Infarction（ESC, ACC, AHA, and WHF）

第五版心肌梗死全球通用定义（与ACC、AHA、WHF联合制定）

北京时间：8月31日 17:15-18:15

2026 ESC Guidelines on Cardiac Rehabilitation

2026 ESC心脏康复指南

北京时间：8月28日 17:00-18:15

1.CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy

CARDIO-TTRansform研究：依普隆特森治疗转甲状腺素蛋白淀粉样变心肌病患者的疗效与安全性

2.SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk

SINGLE-AF研究：中度卒中风险房颤患者的抗凝治疗

3.POET-II: tailored duration antibiotic treatment for infectious endocarditis

POET-II研究：感染性心内膜炎的个体化抗生素疗程

4.ACACIA-HCM:Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy

ACACIA-HCM研究：Aficamten治疗症状性非梗阻性肥厚型心肌病

5.CMR GUIDE: cardiac magnetic resonance GUIDEd management of mild-moderate left ventricular systolic dysfunction with an ICD

CMR GUIDE研究：心脏磁共振指导的轻中度左心室收缩功能障碍伴ICD患者的管理

北京时间：8月29日 14:15-15:45

6.STAREE: Statins for Reducing Events in the Elderly

STAREE研究：他汀类药物用于减少老年人心血管事件的研究

7.AMUNDSEN: Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction

AMUNDSEN研究：急性心肌梗死经皮冠状动脉介入治疗前使用依洛尤单抗

8.TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk

TRANQUILITY研究：帕西贝奇单抗（IL-6配体单抗）每月及每季度给药方案针对高心血管风险慢性肾脏病炎症的疗效

9.REACT - Prevalence of silent atherosclerosis across adult life

REACT研究：成年各年龄段无症状动脉粥样硬化的患病率

10.ENRICH-AF: Edoxaban in intracranial hemorrhage survivors with atrial fibrillation

ENRICH-AF研究：艾多沙班用于伴房颤的颅内出血存活者

11.DAN-RSV: RSVpreF vaccine for preventing cardiorespiratory hospitalisations

DAN-RSV研究：RSVpreF疫苗用于预防心肺相关住院

北京时间：8月29日 17:00-18:15

12.LIBREXIA ACS: Milvexian after recent ACS

LIBREXIA ACS研究：近期急性冠脉综合征后使用米尔维先

13.PREMIUM: Aspirin Omission at the Time of Primary PCI in STEMI

PREMIUM研究：STEMI患者直接PCI术中省略阿司匹林

14.SWITCH SWEDEHEART - Switching from ticagrelor to prasugrel in patients with ACS

SWITCH SWEDEHEART研究：急性冠脉综合征患者从替格瑞洛转换为普拉格雷

15.A-CLOSE: Clopidogrel vs Extended DAPT after High-Risk PCI

A-CLOSE研究：高危PCI术后氯吡格雷 vs. 延长DAPT

16.EPIDAURUS

EPIDAURUS研究

北京时间：8月29日 22:15-23:15

17.PRESC1SE-MI: Safety and efficacy of the ESC 0/1-hour algorithm

PRESC1SE-MI研究：ESC 0/1小时算法的安全性与有效性

18.Performance of 0/1-hour versus standard care pathways in myocardial infarction: a systematic review and IPDMA

0/1小时方案与标准诊疗流程在心肌梗死中的表现比较：系统综述与个体参与者数据荟萃分析

19.AIR-STEMI trial: Functional Coronary Angiography in STEMI

AIR-STEMI研究：功能学冠状动脉造影在STEMI中的应用

20.TARGET-CTCA - Troponin in acute chest pain to guide CTCA

TARGET-CTCA研究：急性胸痛中肌钙蛋白用于指导CTCA

北京时间：8月29日 23:30-00:35

21.EMAIL-HF: Implementation of SGLT2 inhibitors in patients with heart failure through a digital strategy

EMAIL-HF研究：通过数字化策略在心力衰竭患者中落实SGLT2抑制剂

22.Remote Exercise SWEDEHEART: a cluster randomized cross-over trial on cardiac telerehabilitation

Remote Exercise SWEDEHEART研究：心脏远程康复的整群随机交叉试验

23.ADHERE-ASCVD: Adaptive Digital Outreach for Statin Adherence

ADHERE-ASCVD研究：针对他汀依从性的自适应数字化外展干预

24.VIRTUES ICD: Virtual E-health system for Implantable Cardioverter Defibrillators and VIRTUES PM: Digital health platform for pacemakers

VIRTUES ICD研究：植入式心律转复除颤器的虚拟电子健康系统及VIRTUES PM研究：起搏器的数字健康平台

北京时间：8月30日 14:15-15:50

25.H-HeFT: Hydralazin-Isosorbide Dinitrate in HFrEF

H-HeFT研究：肼苯哒嗪-硝酸异山梨酯在HFrEF中的应用

26.H-ISDN Meta-Analysis: Hydralazine-Isosorbide Dinitrate in HFrEF

H-ISDN荟萃分析：肼苯哒嗪-硝酸异山梨酯在HFrEF中的荟萃分析

27.Met-HeFT: Metformin and chronic heart failure

Met-HeFT研究：二甲双胍与慢性心力衰竭

28.MLUMINARA: a prospective RCT of a once daily oral relaxin agonist for treating heart failure

Met-HeFT荟萃分析：二甲双胍在心力衰竭和缺血性心脏病中的应用：系统综述与荟萃分析

29.LUMINARA: a prospective RCT of a once daily oral relaxin agonist for treating heart failure

LUMINARA研究：每日一次口服松弛素激动剂治疗心力衰竭的前瞻性随机对照试验

30.PADN-PH-LHD: PADN for patients with PH from heart failure

PADN-PH-LHD研究：经皮去肺动脉神经术用于心力衰竭所致肺动脉高压患者

陈绍良

31.TIME-HF: Team-based collaborative care model in Heart Failure

TIME-HF研究：心力衰竭中的团队协作式照护模式

北京时间：8月30日 17:00-18:15

32.The POPular ACE TAVI trial: routine or selective protamine administration after TAVI?

POPular ACE TAVI研究：TAVI术后常规还是选择性给予鱼精蛋白？

33.TAVI PCI: Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention

TAVI PCI研究：经导管主动脉瓣植入术与经皮冠状动脉介入治疗

34.TRIC-I-HF: Tricuspid Intervention in Heart Failure

TRIC-I-HF研究：心力衰竭中的三尖瓣介入治疗

35.ACASA-TAVI : Antithrombotic therapy after TAVI

ACASA-TAVI研究：TAVI术后的抗血栓治疗

36.NOTION-4. Subclinical leaflet thrombosis after TAVI

NOTION-4研究：TAVI术后亚临床瓣叶血栓形成

北京时间：8月30日 22:15-23:15

37.AFFIRMO - Atrial Fibrillation integrated approach in FraIl, multimoRbid and polyMedicated Older people

AFFIRMO研究：房颤在衰弱、多病共存及多重用药老年人中的整合管理策略

38.PVI-SHAM-AF: Pulmonary Vein Isolation versus SHAM in AF

PVI-SHAM-AF研究：肺静脉隔离对比假手术（SHAM）治疗房颤

39.NEXAF - Long-term exercise in patients with non-permanent atrial fibrillation

NEXAF研究：非持续性房颤患者的长期运动干预

40.IDEAL-AF: Individualised Low Voltage Ablation in Persistent AF

IDEAL-AF研究：持续性房颤中的个体化低电压区消融

北京时间：8月30日 23:30-00:30

41.SHASTA-3/4 12-Month Results

SHASTA-3/4研究：12个月结果

42.CRHCP: Long-Term Blood Pressure Control and Dementia Risk

CRHCP研究：长期血压控制与痴呆风险

孙英贤

43.Blood Pressure-Lowering Treatment Across the Spectrum of Cardiovascular Risk

跨不同心血管风险谱系的降压治疗

44.ECLIPSE-CKD: Salt Substitute in Chronic Kidney Disease

ECLIPSE-CKD研究：慢性肾脏病中的盐替代品

Shui Dong

北京时间：8月31日 14:15-15:30

45.ASPIRED: Multi-centre open label randomised controlled trial of immediate enhanced ambulatory ECG monitoring versus standard monitoring in acute unexplained syncope patients

ASPIRED研究：即时强化动态心电图监测对比标准监测在急性不明原因晕厥患者中的多中心开放标签随机对照试验

46.DANISH-CRT: Targeted LV lead placement for biventricular pacing for heart failure

DANISH-CRT研究：靶向左心室导线植入用于心力衰竭双心室起搏

47.SyncAV PMT: Clinical Benefit of Dynamic AV Optimization in CRT

SyncAV PMT研究：CRT中动态房室优化的临床获益

48.Syncope-Stopper: Upfront Pacing vs Standard Care in High-Risk Unexplained Syncope

Syncope-Stopper研究：早期起搏对比标准治疗在高危不明原因晕厥中的应用

49.HIS Alternative II

HIS Alternative II研究

北京时间：8月31日 19:00-20:00

50.EVAOLD: Evaluation of reperfusion stategies in elderly patients

EVAOLD研究：老年患者再灌注策略的评估

51.ISOLEDS: IVUS vs OCT Guidance for PCI of Distal Left Main Bifurcation Lesions

ISOLEDS研究：IVUS对比OCT指导远端左主干分叉病变PCI

曾勇

52.CorCal Study: Pooled Cohort Equations versus Coronary Artery Calcium Score in ASCVD Primary Prevention

CorCal研究：汇集队列方程对比冠状动脉钙化积分在ASCVD一级预防中的应用

53.CoCAP Study: Graft Patency in ACS patients treated with DAPT or single Aspirin after CABG

CoCAP研究：CABG术后接受DAPT或阿司匹林单药治疗的ACS患者桥血管通畅率

北京时间：8月31日 20:15-21:15

54.DISCO trial: Acute coronary angiography after resuscitated out-of-hospital cardiac arrest without ST-elevation on the ECG

DISCO研究：院外心脏骤停复苏成功后ECG无ST段抬高患者的急诊冠状动脉造影

55.CAG after OHCA without ST-elevation

无ST段抬高的院外心脏骤停后行冠状动脉造影

56.The HeartRunner Trial: Out-of-Hospital Cardiac Arrest Survival following Community First Responder activation

HeartRunner研究：社区第一响应者激活后院外心脏骤停的生存率

57.Prague 26: catheter-directed thrombolysis for pulmonary embolism

Prague 26研究：导管定向溶栓治疗肺栓塞

58.LAACS-2. Left Atrial Appendage Closure with Surgery-2

LAACS-2研究：外科手术同期左心耳封堵-2

北京时间：8月28日 14:15-15:45

1.Initial Evaluation with Combined CT Perfusion and Angiography for Suspected NSTEMI: Impact on Invasive Coronary Angiography Utilization and Coronary Etiology Detection

对疑似NSTEMI患者行CT灌注与CT血管造影联合初始评估：对有创冠状动脉造影使用率及冠状动脉病因检出率的影响

李晨光

2.Coronary CT Angiography to Guide Lipid Management in an Asymptomatic Community-Based Population

冠状动脉CT血管造影用于指导无症状社区人群的血脂管理

郭翔

3.Addition of Computed Tomography-derived Fractional Flow Reserve in the diagnostic pathway of patients with stable coronary artery disease: the FUSION randomized trial

在稳定性冠状动脉疾病患者诊断路径中增加CT衍生的血流储备分数：FUSION随机试验

4.The DANish COronary DEcalcification trial

丹麦冠状动脉钙化病变干预试验

5.Predictive value of total coronary atherosclerotic volume detected by an automated deep learning-based algorithm in a general population - A SCAPIS Cohort Analysis

基于自动化深度学习算法检测的冠状动脉总粥样硬化体积在一般人群中的预测价值——SCAPIS队列分析

6.Coronary Computed Tomographic Angiography to Optimize the Diagnostic Yield of Invasive Angiography for Low-Risk Patients Screened With Artificial Intelligence

冠状动脉CT血管造影用于优化经人工智能筛查的低风险患者有创冠状动脉造影的诊断阳性率

北京时间：8月28日 14:15-15:45

7.The Vericiguat in Vasospastic Angina (ViVA) trial: a double-blind placebo-controlled randomized cross-over study

Vericiguat治疗血管痉挛性心绞痛（ViVA）试验：一项双盲、安慰剂对照、随机交叉研究

8.Incremental diagnostic value of coronary microvascular dysfunction testing in patients with a working diagnosis of myocardial infarction with nonobstructive coronary arteries by stress CMR

负荷心脏磁共振诊断为MINOCA的患者进行冠脉微血管功能障碍检测的额外诊断价值

9.Microvascular Resistance Reserve and Cardiovascular Outcomes: Prespecified Analysis of FLOW-CMD

微血管阻力储备与心血管结局：FLOW-CMD的预设分析

10.The DiagnOsis of MINOCA (DOMINO) registry: a real-world use of multimodality imaging and its impact on etiologic classification

MINOCA诊断（DOMINO）登记研究：多模态影像在真实世界中的应用及其对病因分类的影响

11.Head-to-head comparison of multiple cardiac magnetic resonance parameters for the detection of CMVD in patients with INOCA: Validation with integrated PET/MRI scanner

多项心脏磁共振参数用于检测INOCA患者中CMVD的头对头比较：以一体化PET/MRI扫描仪进行验证

12.CMR-Derived Epicardial Adipose Tissue Differentiates Etiologies and Predicts Outcomes in Patients With Suspected MINOCA

心脏磁共振衍生的心外膜脂肪组织可鉴别疑似MINOCA患者的病因并预测结局

陈文苏

北京时间：8月28日 17:00-18:00

13.Mortality and hospitalization rates in 19,397 participants according to ejection fraction phenotype and country income level: The Global Congestive Heart Failure Registry.

根据射血分数表型和国家收入水平分层的19,397名参与者的死亡率和住院率：全球充血性心力衰竭登记研究

14.ECG Flow ATTR: Artificial Intelligence Enabled Early Diagnosis of Transthyretin Cardiac Amyloidosis Using Electrocardiography

ECG Flow ATTR研究：基于心电图的人工智能辅助转甲状腺素蛋白心脏淀粉样变早期诊断

15.Personalised Evaluation of NT-proBNP and Clinical Characteristics in Suspected Heart Failure

疑似心力衰竭患者中NT-proBNP及临床特征的个体化评估

16.Proactive screening identifies unrecognized heart failure after ST-elevation myocardial infarction

主动筛查可识别ST段抬高型心肌梗死后未被识别的心力衰竭

北京时间：8月28日 19:45-21:00

17.EuroHeart - TAVI Registry

EuroHeart—TAVI登记研究

18.Optimal Medical Treatment With or Without Valve Repair in Patients with symptomatic Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: a multicenter, randomized comparison

有症状反常低流量、低跨瓣压差主动脉狭窄患者单纯优化药物治疗对比优化药物治疗加瓣膜修复：一项多中心随机对照研究

19.Efficacy and safety of routine post-dilatation using a balloon-expandable transcatheter aortic valve implantation platform - the randomized controlled DUOTAP trial

球囊扩张式经导管主动脉瓣置入系统术后常规后扩张的疗效与安全性——DUOTAP随机对照试验

20.EMPagliflozin after Aortic Valve Replacement study: a randomized clinical trial

主动脉瓣置换术后恩格列净应用研究：一项随机临床试验

21.Prosthesis-Patient Mismatch after Transcatheter or Surgical Treatment of Aortic Valve Stenosis: A Sub-Study of the Randomized DEDICATE-DZHK6 Trial

经导管或外科手术治疗主动脉瓣狭窄后的瓣膜-患者不匹配：随机DEDICATE-DZHK6试验的亚组研究

北京时间：8月28日 22:15-23:15

22.Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia

血管生成素样蛋白3抗体rivocibart治疗纯合子家族性高胆固醇血症

彭道泉

23.Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3

靶向ANGPTL3的CRISPR-Cas9基因编辑疗法CTX310的疗效持久性

24.AAV8-mediated gene therapy for homozygous familial hypercholesterolemia

AAV8介导的基因治疗用于纯合子家族性高胆固醇血症

25.Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study

单剂量Kylo-11后Lp(a)的极长持续时间降低：首次人体研究的最终数据

北京时间：8月29日 14:15-15:45

26.Long-term effectiveness of intensive blood pressure management led by non-physician community health-care providers on cardiovascular events: 7-year follow-up of a cluster randomised trial

非医生社区卫生保健提供者主导的强化血压管理对心血管事件的长期有效性：一项整群随机试验的7年随访结果

孙英贤

27.A Multicomponent, Technology-Enabled Primary Care Intervention to Improve Cardiometabolic Risk Factors Control in Underserved Communities: The CHArMING Cluster-Randomized Trial

一项多组分、技术赋能的初级保健干预措施以改善医疗服务不足社区的心代谢危险因素控制：CHArMING整群随机试验

28.Integrated Echocardiographic Screening for Rheumatic Heart Disease During Antenatal Care: A Cluster Randomized Crossover Trial

产前保健中整合超声心动图筛查风湿性心脏病：一项整群随机交叉试验

29.SALT: A randomised controlled trial of potassium-enriched salt substitution in adolescents and their families in Soweto, South Africa

SALT研究：南非索韦托对青少年及其家庭进行富钾食盐替代的随机对照试验

30.Comparison of ESC and NICE Guidelines-recommended Initial Diagnostic Strategies in Patients with Stable Chest Pain: the OPERATE Randomized and Double-blinded Trial

ESC和NICE指南推荐的稳定性胸痛患者初始诊断策略比较：OPERATE随机双盲试验

周伽

31.Documenting the gap between current European practice in secondary prevention and the new ESC guidelines on cardiac rehabilitation: Principal results from the EUROASPIRE VI survey in 27 countries

记录当前欧洲二级预防实践与新ESC心脏康复指南之间的差距：EUROASPIRE VI调查在27个国家的主要结果

北京时间：8月29日 17:00-18:15

32.Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE Outcomes Study

Ralinepag治疗改善结缔组织病相关肺动脉高压患者的预后：3期ADVANCE结局研究结果

33.Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial

左西孟旦用于射血分数保留的心力衰竭所致肺动脉高压患者：LEVEL试验结果

34.Automated Detection of Pulmonary Hypertension from a Single Apical Four-Chamber Echocardiographic Clip: development on the largest RHC-confirmed cohort to date and multinational external validation

基于单个心尖四腔心超声切面的肺动脉高压自动检测：在迄今为止最大的经右心导管确诊队列上开发并进行多国外部验证

35.Pulmonary Arterial Hypertension in Families with Hereditary Hemorrhagic Telangiectasia: A Nationwide Family Registry

遗传性出血性毛细血管扩张症家系中的肺动脉高压：一项全国性家系登记

周玉平

36.ARTISAN: Afterload Reduction To Improve Right Ventricular Structure And FuNction

ARTISAN：减少后负荷以改善右心室结构和功能

北京时间：8月29日 19:45-21:00

37.EnVast thrombectomy device as adjunctive reperfusion modality in ST-segment elevation myocardial infarction

EnVast血栓抽吸装置作为ST段抬高型心肌梗死的辅助性再灌注手段

38.Time-dependent effects of physiology-guided staged complete revascularisation in ST-segment elevation myocardial infarction with MVD disease: a multicentre, open -labelled, randomised STAGED trial

生理学指导的分步完全血运重建对合并多支血管病变的STEMI患者的时间依赖性效应：一项多中心、开放标签随机STAGED研究

王焱

39.Percutaneous coronary intervention using sirolimus eluting balloons in patients at high bleeding risk: Evidence from the SELUTION DeNovo trial

使用西罗莫司洗脱球囊对高出血风险患者行经皮冠脉介入治疗：SELUTION DeNovo试验证据

40.Immediate Versus Deferred Percutaneous Coronary Intervention in Clinically Stable Patients with STEMI Presenting Beyond 12 Hours of Symptom Onset - The LATE-MI Randomized Trial

症状发作超过12小时就诊的临床稳定STEMI患者中，即刻与延迟经皮冠状动脉介入治疗的比较——LATE-MI随机试验

41.Aspirin Discontinuation 1-month After PCI in Acute Myocardial Infarction: Individual-patient-data pooled analysis of the TARGET-FIRST and ULTIMATE-DAPT randomized trials

急性心肌梗死患者PCI术后1个月停用阿司匹林：TARGET-FIRST和ULTIMATE-DAPT随机试验的个体患者数据汇总分析

北京时间：8月29日 19:45-21:00

42.Hybrid Versus Catheter Ablation for Persistent Atrial Fibrillation and Heart Failure: The HALT AF Randomised Trial

混合消融对比导管消融治疗持续性房颤合并心力衰竭：HALT AF随机试验

43.Pulmonary Vein Isolation with Pulsed Field Ablation with versus without Posterior Wall Ablation in Patients with Symptomatic Persistent Atrial Fibrillation

有症状的持续性房颤患者中，脉冲场消融肺静脉隔离联合或不联合后壁消融的比较

44.Pulsed-Field Ablation With/Without Electrogram Mapping of Key Substrates for Non-paroxysmal Atrial Fibrillation: A Prospective Multicenter Randomized Study (PEAK-AF Study)

非阵发性房颤关键基质的脉冲场消融伴/不伴电图标测：一项前瞻性多中心随机研究（PEAK-AF研究）

李凯歌

45.12-month safety and effectiveness of a dual energy focal pulsed field ablation system to treat paroxysmal atrial fibrillation: results from the FlexPulse IDE study

双能量局灶脉冲场消融系统治疗阵发性房颤的12个月安全性和有效性：FlexPulse IDE研究结果

46.AI-Guided Shared Decision-Making for Optimizing Patient Selection in Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial (AI-PAFA Trial)

人工智能辅助的共同决策优化房颤导管消融患者筛选：一项随机临床试验（AI-PAFA试验）

北京时间：8月29日 22:15-23:15

47.Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial

Aficamten对有症状的非梗阻性肥厚型心肌病患者心脏结构和功能的影响——ACACIA-HCM试验结果

48.Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM

Aficamten与美托洛尔单药治疗梗阻性肥厚型心肌病的比较：基于MAPLEHCM试验前治疗情况

49.Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation

基于超声心动图的深度学习模型用于肥厚型心肌病的检测、表型鉴定及左心室压差估计：开发与多国外部验证

50.Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE

玛伐凯泰治疗梗阻性肥厚型心肌病患者长达5年的安全性和有效性：MAVA-LTE最终结果

北京时间：8月29日 23:30-00:30

51.Early or late, benefits of digoxin reconsidered in HFrEF: Insights from the Digitalis Investigation Group Trial (DIG)

无论早期还是晚期，重新审视地高辛在HFrEF中的获益：来自洋地黄研究组（DIG）试验的启示

52.Efficacy of digitoxin over time in patients with HFrEF: further analysis of DIGIT-HF

洋地黄毒苷在HFrEF患者中随时间变化的有效性：DIGIT-HF的进一步分析

53.Low-dose Digoxin in Women and Men with Heart Failure: Data from DECISION

低剂量地高辛用于男性和女性心力衰竭患者：DECISION研究数据

54.Long-term cost-effectiveness of digitoxin in heart failure with reduced ejection fraction analyzed in DIGIT-HF

基于DIGIT-HF的洋地黄毒苷在射血分数降低的心力衰竭中的长期成本效果分析

北京时间：8月29日 23:30-00:30

55.Modified HEART Score Triage With Point-of-Care hs-cTnI in Suspected ACS: Clinical Outcomes in the HARTc 2.0 Randomized Trial

改良HEART评分结合床旁高敏肌钙蛋白I对疑似ACS进行分诊：HARTc 2.0随机试验的临床结局

56.The Long-cTnT/hs-cTnT Ratio as a Novel Discriminator Between Takotsubo Syndrome and Acute Coronary Syndrome

Long-cTnT/hs-cTnT比值作为鉴别Takotsubo综合征与急性冠状动脉综合征的新型指标

57.A Clinical Decision Rule with High-Sensitivity Troponin to Rule Out Acute Coronary Syndrome in Primary Care (POB HELP): A Diagnostic Trial

初级保健中使用高敏肌钙蛋白排除急性冠脉综合征的临床决策规则（POB HELP）：一项诊断试验

58.Ischaemic Conditioning in High-Risk ST-elevation Myocardial Infarction: The Randomized, Multicentre, RIP-HIGH Trial

高危ST段抬高型心肌梗死中的缺血适应：RIP-HIGH随机多中心试验

北京时间：8月30日 14:15-15:45

59.The Personal Plaque Threshold: A Causal AI Biological World Model for Selecting Individualized LDL Targets to Personalize Cardiovascular Prevention

个体化斑块阈值：基于因果AI生物全域模型制定个体化LDL目标值，实现个体化心血管疾病预防

60.Risk of Ischemic Stroke With Beta-Blockers: Evidence From Randomized Clinical Trials

β受体阻滞剂与缺血性卒中风险：来自随机临床试验的证据

61.Cardiometabolic parameters by the degree of maintenance of weight reduction in tirzepatide-treated adults with obesity: post hoc study of SURMOUNT MAINTAIN Trial

替尔泊肽治疗的肥胖成人中体重减轻维持程度对心脏代谢参数的影响：SURMOUNT MAINTAIN试验的事后分析

62.High-Intensity Interval Training Reduces 10-Year Mortality in Older Adults: The Generation 100 Randomized Controlled Trial

高强度间歇训练降低老年人10年死亡率：Generation 100随机对照试验

63.Machine learning and hemodynamic profile-based clinical decision support systems for personalized guideline-concordant antihypertensive treatment in primary care (LIGHT-precision)

用于初级保健中个体化且符合指南的降压治疗的基于机器学习与血流动力学特征的临床决策支持系统（LIGHT-precision）

郑昕

64.BetaBlocker discontinuation in patients with chronic coronary syndrome, prior myocardial infarction: a pooled analysis of the ABYSS and SMART-DECISION randomised trials

既往心肌梗死的慢性冠脉综合征患者停用β受体阻滞剂：ABYSS与SMART-DECISION随机试验的合并分析

北京时间：8月30日 14:15-15:45

65.Danicamtiv, a Novel Cardiac Myosin Activator, Is Associated with Improved Right Ventricular Function: pre-clinical and clinical evidence in patients with DCM

新型心肌肌球蛋白激动剂Danicamtiv与右心室功能改善有关：扩张型心肌病临床前及临床研究证据

66.Ambient Air Pollution Associates with Dose-Dependent Loss of the Y Chromosome via IL6R Inflammatory Signalling and Adverse Cardiovascular Outcomes: From 200,000 Men to Single Bone Marrow Cells

环境空气污染通过IL6R炎症信号与剂量依赖性的Y染色体丢失及不良心血管结局相关：从20万名男性到单个骨髓细胞

67.Dynamic DPP3 profiling for rapid bedside risk stratification in acute myocardial infarction-related cardiogenic shock

动态DPP3检测用于急性心肌梗死相关心源性休克的床旁快速风险分层

68.Deciphering Reticulated Platelets Across Chronic and Acute Coronary Syndromes：Transcriptomic and Proteomic Evidence for S100A8/9-TLR4 Signaling dysregulation

解析慢性和急性冠脉综合征中的网织血小板：S100A8/9-TLR4信号失调的转录组学和蛋白质组学证据

69.Fine-tuned mTORC1 inhibition preserves inflammatory signature in liver and heart to rescue HFpEF

精细调控mTORC1抑制可维持肝脏与心脏炎症特征以改善HFpEF

70.Macrophage RNASET2 is associated with activation of innate RNA-sensing program in heart failure with preserved ejection fraction

巨噬细胞RNASET2与射血分数保留的心力衰竭中先天免疫RNA感知程序的激活相关

北京时间：8月30日 17:00-18:00

71.A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

前列腺癌患者心血管及生活方式危险因素随机干预研究

72.An open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2 targeted therapy related cardiac dysfunction

一项开放标签、随机对照试验，评估对已恢复的HER2靶向治疗相关心功能不全患者停用药物的安全性

73.Incidence and Predictors of Arterial Thrombosis in Cancer Patients: The Prospective COMPASS-Arterial Cancer Associated Thrombosis (COMPASS-ARTeCAT) Study

癌症患者动脉血栓的发生率与预测因素：前瞻性COMPASS-动脉性癌症相关血栓（COMPASS-ARTeCAT）研究

74.Heart Failure and Incident Hematologic Malignancies: A Nationwide Population-Based Cohort Study

心力衰竭与新发血液系统恶性肿瘤：一项全国性基于人群的队列研究

北京时间：8月30日 19:45-21:00

75.A Phase 3 Clinical Trial of I124-evuzamitide to Diagnose Cardiac Amyloidosis

I124-evuzamitide诊断心脏淀粉样变的III期临床试验

76.Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial

CARDIO-TTRansform试验中，转甲状腺素蛋白基因沉默剂eplontersen在接受稳定剂治疗的转甲状腺素蛋白淀粉样变性心肌病患者中的有效性和安全性

77.Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy

Vutrisiran在伴心肌病的转甲状腺素蛋白淀粉样变性中的疗效：按基线Tafamidis使用情况分析

78.A Meta-Analysis of Gene Silencer Therapy in ATTR-CM

ATTR-CM中基因沉默治疗的荟萃分析

79.Effect of anselamimab on cardiac structure and function in patients with light chain amyloidosis: The CARES trials

Anselamimab对轻链淀粉样变性患者心脏结构和功能的影响：CARES试验

北京时间：8月30日 19:45-21:00

80.Effects of finerenone in patients with hypertensive nephropathy

非奈利酮在高血压肾病患者中的治疗作用

81.Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension

KARDINAL试验的延长随访：评估Tonlamarsen在未控制高血压中的疗效

82.Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies

在逆转原发性醛固酮增多症所致心脏重构方面，抑制醛固酮比降低血压更有效：MATCH和PATHWAY-1前瞻性CMR亚研究

83.Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial

Baxdrostat在未控制或难治性高血压患者中的长期有效性和安全性：BaxHTN III期试验结果

84.Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)

非奈利酮在慢性肾脏病伴心血管疾病患者中的有效性和安全性：个体参与者数据合并分析（INFINITY）

北京时间：8月30日 22:15-23:15

85.Randomised intravenous iron trials for heart failure: an individual-patient-data meta-analysis

静脉铁剂治疗心力衰竭的随机试验：一项患者个体化数据的荟萃分析

86.Effect of In-Hospital Initiation of Dapagliflozin on Decongestion-Related Endpoints in Acute Heart Failure: A Prespecified Analysis of the DAPA ACT HF-TIMI 68 Trial

住院期间启动达格列净对急性心力衰竭去充血相关终点的影响：DAPA ACT HF-TIMI 68试验的预设分析

87.Obesity, Frail Obesity, and Clinical Outcomes with a Fully Magnetically Levitated Left Ventricular Assist Device: the MOMENTUM 3 Trial

肥胖、虚弱性肥胖与全磁悬浮左心室辅助装置的临床结局：MOMENTUM 3试验

88.Evolving Trends in Treatments, Morbidity, and Mortality in Heart Failure: 30 Years of Data from the Italian Network of Heart Failure (IN-HF) Registry

心力衰竭治疗、发病率和死亡率的演变趋势：来自意大利心力衰竭网络（IN-HF）登记的30年数据

北京时间：8月30日 23:30-00:30

89.Prevention in Healthcare Professionals and the General Population: Insights from the ESC Congress 2025 Cardiovascular Health Check

医疗专业人员和普通人群的预防：ESC 大会2025心血管健康检查的见解

90.Global Patterns of Wealth-Related Cardiometabolic Care Cascade Inequalities and Their Impact on Predicted 10-Year Cardiovascular Risk

全球财富相关心血管代谢照护级联不平等的格局及其对预测10年心血管风险的影响

91.Global patterns of blood pressure lowering and projected cardiovascular disease and mortality

全球降压模式及预测的心血管疾病和死亡率LAA

92.THe Sub-Saharan Africa Survey of Heart Failure II - Regional Perspectives

撒哈拉以南非洲心力衰竭调查II——区域视角

北京时间：8月30日 23:30-00:30

93.Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study

沙库巴曲/阿利沙坦联合氨氯地平在氨氯地平或沙库巴曲/阿利沙坦单药控制不佳的高血压患者中的有效性和安全性：SALUS研究

李建平

94.The ELFIE-HYPERTENSION Trial: An international randomized multicenter trial of an artificial intelligence enhanced and gamified mobile health intervention for hypertension management

ELFIE-HYPERTENSION试验：一项关于人工智能增强和游戏化移动健康干预用于高血压管理的国际随机多中心试验

95.Blood pressure management with an artificial intelligence-enhanced app and wearable devices: My Intelligent Cardiac Assistant (MICArdiac) Randomised Controlled Trial

基于人工智能增强的应用和可穿戴设备的血压管理：My Intelligent Cardiac Assistant（MICArdiac）随机对照试验

96.Chemical adherence testing-guided intervention is cost-effective in management of non-adherence to antihypertensive treatment - life-time evaluation of OUTREACH Study

化学依从性检测指导的干预在管理抗高血压治疗不依从方面具有成本效果——OUTREACH研究的终身评估

北京时间：8月31日 14:15-15:45

97.Improving esophageal protection during AF ablation: a multicenter randomized controlled trial

改善房颤消融期间的食管保护：一项多中心随机对照试验

98.Left atrial posterior isolation in addition to pulmonary vein isolation in patients with persistent AF refractory to pharmacologic cardioversion: The LEAP-AF randomized clinical trial

在药物复律无效的持续性房颤患者中，除肺静脉隔离外增加左心房后壁隔离：LEAP-AF随机临床试验

99.Additional Low-Voltage-Area ablation During Atrial Fibrillation Rhythm In Patients With Persistent Atrial Fibrillation: a prospective, randomized clinical trial

持续性房颤患者在房颤节律期间追加低电压区消融：一项前瞻性随机临床试验

朱雪峰

100.A Randomised Controlled Trial of Ripple Mapping-guided isthmus ablation versus Local Activation Time-guided ablation in Atrial Tachycardia: The Ripple AT-plus study

Ripple Mapping引导的峡部消融与局部激动时间引导的消融治疗房性心动过速的随机对照试验：Ripple AT-plus研究

101.A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint versus Prespecified Ablation Strategy Followed by Cardioversion in Patients with Persistent

以房颤终止作为手术终点的消融与预设消融策略后复律在持续性房颤患者中的随机对照研究

宋子良

102.The FLEX-PVI Trial: High-Power Short-Duration Pulmonary Vein Isolation Using a Flexible-Tip Contact Force-Sensing Catheter

FLEX-PVI试验：采用柔性尖端接触力感应导管的高功率短时程肺静脉隔离

北京时间：8月31日 14:15-15:45

103.Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial

英克司兰与贝派地酸降低LDL-C的头对头比较：在高和极高心血管风险患者中的4期VICTORION-CHALLENGE试验结果

104.Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study

口服HRS-5346，一种新型小分子脂蛋白(a)抑制剂，在脂蛋白(a)升高且心血管高风险成人中的2期随机双盲研究

朱丹

105.Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial

基于方案的急性冠脉综合征患者早期强化降脂管理（BRIDGE）：一项多中心前瞻性整群随机对照试验

106.A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)

一项评估vsa003注射液在中国青少年和成人纯合子家族性高胆固醇血症患者中有效性和安全性的III期临床试验

田庄

107.Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial

依洛尤单抗对既往无心肌梗死或卒中患者致死性结局的影响：VESALIUS-CV试验的预设分析

108.Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)

靶向Lp(a)的长效siRNA类药物Lepodisiran对氧化磷脂的作用

北京时间：8月31日 17:15-18:15

109.Outcomes of Intracoronary AAV1/SERCA2a Gene Therapy in Patients With Heart Failure With Preserved Ejection Fraction: 12-Month Results From the MUSIC-HFpEF Phase 1/2a Trial

冠脉内AAV1/SERCA2a基因治疗在射血分数保留的心力衰竭患者中的结局：MUSIC-HFpEF 1/2a期试验的12个月结果

110.CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy

CIRRUS-HCM：新型心脏肌节调节剂EDG-7500在非梗阻性和梗阻性肥厚型心肌病中的安全性和有效性的12周评估

111.The autoregulated bioprosthetic total artificial heart in advanced biventricular failure: 180-day outcomes from the EFICAS study

自动调节型生物人工全心脏在晚期双心室衰竭中的180天结局：EFICAS研究

112.Intravenous Dexrazoxane for Hemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial (SHIELD-MI)

静脉注射右雷佐生用于STEMI中出血性心肌梗死：一项双盲、安慰剂对照、序贯队列IIa期试验（SHIELD-MI）

北京时间：8月31日 17:15-18:15

113.Predictors of treatment response in acute intermediate-risk pulmonary embolism: analysis from the HI-PEITHO randomized study

急性中危肺栓塞治疗反应的预测因素：来自HI-PEITHO随机研究的分析

114.Reperfusion Strategies for Intermediate-Risk Pulmonary Embolism: A Meta-analysis

中危肺栓塞的再灌注策略：一项荟萃分析

115.An AI-driven Model to Improve Prediction of Early Mortality in Acute Pulmonary Embolism: The VITAL-PE Score

AI驱动模型提高急性肺栓塞早期死亡率预测：VITAL-PE评分

116.Rapid expansion of catheter-directed therapies for pulmonary embolism in Germany: A nationwide analysis of trends and outcomes

德国导管介入治疗肺栓塞的迅速扩展：一项全国性趋势与结局分析

北京时间：8月31日 19:00-20:00

117.Kidney Function Decline, Heart Failure Hospitalization and the Effect of Empagliflozin in Heart Failure: An EMPEROR-Pooled Analysis

肾功能下降、心力衰竭住院及恩格列净在心力衰竭中的疗效：EMPEROR汇总分析

118.Glomerular filtration rate slope as a surrogate endpoint for kidney disease progression in heart failure trials: An individual participant data meta-analysis

肾小球滤过率斜率作为心力衰竭试验中肾脏疾病进展的替代终点：个体参与者数据荟萃分析

119.Predicting Short-term Effects on Blood Pressure, Kidney Function, and Serum Potassium with Heart failure Therapies and their Combinations

预测心力衰竭治疗及其联合方案对血压、肾功能和血清钾的短期影响

120.Precision Phenotyping of Multi-Organ Fat Distribution Defines Distinct Cardiorenal-Metabolic and Heart Failure Risk Profiles

多器官脂肪分布的精准表型分析定义了不同的心肾代谢和心力衰竭风险特征

北京时间：8月31日 19:00-20:00

121.Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial

左心耳封堵术后半量抗凝 vs. 标准抗血小板预防隐匿脑栓塞的疗效：HALO-SCE随机试验

居维竹

122.Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian

OCEANIC-STROKE研究中随机化后前90天的双联抗血小板治疗：参与者特征及与asundexian的交互作用

123.Sex-Specific Outcomes of Left Atrial Appendage Closure Versus Medical Therapy: The CLOSURE-AF-DZHK-16 Trial

左心耳封堵术与药物治疗的性别特异性结局：CLOSURE-AF-DZHK-16试验

124.Left Atrial Appendage Closure as an Alternative to NOAC for Stroke Prevention in Patients with Atrial Fibrillation at Low Bleeding Risk: A Patient-Level Meta-Analysis

左心耳封堵作为低出血风险房颤患者卒中预防中NOAC的替代方案：一项患者水平荟萃分析

北京时间：8月31日 20:15-21:15

125.Primary Results of the VHD-W (Valvular Heart Disease in Women) Study

VHD-W（女性瓣膜性心脏病）研究的主要结果

126.Medium-term outcomes following contemporary transcatheter aortic valve implantation in England: insights from national registry linkage

基于全国登记数据库关联分析的临床启示：英格兰现代经导管主动脉瓣植入术后的中期预后

127.Isolated Tricuspid Valve Replacement at 20-Year Follow-up. Insight from the largest multicenter international registry. DURABLE Tricuspid

孤立性三尖瓣置换术20年随访：来自最大规模国际多中心登记DURABLE Tricuspid的洞见

128.How Much Tricuspid Regurgitation Reduction Is Enough? Residual TR and Long-Term Outcomes After T-TEER in the Randomized TRI-FR Extension

需要减少多少三尖瓣反流才足够？TRI-FR延伸随机研究中T-TEER术后残余三尖瓣反流与长期结局

北京时间：8月31日 20:15-21:15

129.Longer-term prognostic benefit of low-dose digoxin versus beta-blockers in patients with permanent atrial fibrillation and symptoms of heart failure

在永久性房颤伴心力衰竭症状患者中，低剂量地高辛对比β受体阻滞剂的长期预后获益

130.Ablate versus Pace in Elderly Patients With Persistent Atrial Fibrillation

老年持续性房颤患者中消融与起搏的比较

131.CANDLE-AF: Comparative effectiveness of noninvasive single-lead ECG monitoring strategies for atrial fibrillation detection after cryptogenic stroke

CANDLE-AF：隐源性卒中后无创单导联心电图监测策略在心房颤动检测方面的比较疗效

132.REAL-PATCH-AF: Real-world performance of self-applied ECG patch systems for atrial fibrillation screening in older adults: a randomized comparison of six systems

REAL-PATCH-AF：自贴式心电图贴片系统在老年房颤筛查中的真实世界性能——六种系统的随机比较

北京时间：8月31日 20:15-21:15

133.Two-Year Outcomes of Intravascular Ultrasound Guided versus Angiography Guided Complex High-Risk Indicated Percutaneous Coronary Intervention

血管内超声引导与血管造影引导的复杂高危指征经皮冠状动脉介入治疗的两年结局

134.Ticagrelor versus Prasugrel in Patients Undergoing Invasive Management of Coronary Artery Disease

替格瑞洛与普拉格雷在接受有创性冠状动脉疾病管理患者中的比较

135.Long-term clinical outcomes in patients with angina and non obstructive coronary artery disease undergoing comprehensive invasive coronary function testing

心绞痛合并非阻塞性冠状动脉疾病且接受全面有创冠脉功能检测患者的长期临床结局

136.Twenty-Year Outcomes of a Randomized Comparison between Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Unprotected Left Main Stem Stenosis

无保护左主干狭窄患者中经皮冠状动脉介入与冠状动脉旁路移植术随机比较的二十年结局

北京时间：8月31日 20:15-21:15

137.Goal-Directed vs Self-Directed Valsalva Maneuver to Improve Patent Foramen Ovale Detection: The BUBBLE Randomized Crossover Trial

目标导向与自我导向Valsalva动作提高卵圆孔未闭检出率的比较：BUBBLE随机交叉试验

138.Impact of stress CT myocardial Perfusion on downstream resources and PROgnosis in patients with suspected or known coronary artery disease: CTP-PRO Study results at 1-year follow-up

负荷CT心肌灌注对疑似或已知冠状动脉疾病患者后续资源利用和预后的影响：CTP-PRO研究1年随访结果

139.Novel 3-dimensional echocardiographic quantification of mitral regurgitant volume

新型三维超声心动图定量二尖瓣反流量

140.Using AI to detect atrial myopathy and predict cardioembolic stroke from routine cardiac CT: the ORFAN-MAESTRIA study

利用AI通过常规心脏CT检测心房肌病并预测心源性卒中：ORFAN-MAESTRIA研究

来源：ESC官网

注：以上日程根据ESC官网截至8月7日已公布的结果整理，最终信息可能存在调整。

如有遗漏或错误，欢迎广大读者提醒及指正。